Blair William & Co. IL Trims Position in Kenvue Inc. $KVUE

Blair William & Co. IL trimmed its stake in Kenvue Inc. (NYSE:KVUE) by 31.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 142,477 shares of the company’s stock after selling 63,910 shares during the period. Blair William & Co. IL’s holdings in Kenvue were worth $2,312,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Kenvue by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock worth $4,881,844,000 after acquiring an additional 4,101,880 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of Kenvue by 27.1% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 310,686 shares of the company’s stock valued at $5,042,000 after purchasing an additional 66,192 shares in the last quarter. Renaissance Capital LLC raised its holdings in shares of Kenvue by 55.8% in the 3rd quarter. Renaissance Capital LLC now owns 980,436 shares of the company’s stock valued at $15,912,000 after purchasing an additional 351,259 shares in the last quarter. Viking Fund Management LLC lifted its position in shares of Kenvue by 36.0% in the 3rd quarter. Viking Fund Management LLC now owns 605,000 shares of the company’s stock worth $9,819,000 after purchasing an additional 160,000 shares during the period. Finally, Allstate Corp bought a new position in shares of Kenvue during the third quarter valued at approximately $1,152,000. 97.64% of the stock is currently owned by institutional investors.

Kenvue Trading Down 1.6%

Shares of Kenvue stock opened at $17.38 on Friday. The company has a current ratio of 0.96, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $25.17. The firm has a market capitalization of $33.30 billion, a price-to-earnings ratio of 22.56, a PEG ratio of 4.01 and a beta of 0.51. The firm’s 50 day simple moving average is $17.89 and its two-hundred day simple moving average is $17.35.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.22 by $0.05. The business had revenue of $3.78 billion during the quarter, compared to the consensus estimate of $3.68 billion. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The business’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.26 earnings per share. Analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th were given a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a yield of 4.8%. Kenvue’s payout ratio is currently 107.79%.

Analysts Set New Price Targets

Several brokerages recently issued reports on KVUE. UBS Group lifted their price objective on shares of Kenvue from $17.00 to $19.00 and gave the company a “neutral” rating in a report on Wednesday, February 18th. Citigroup upped their target price on Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, February 18th. Barclays increased their target price on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Friday, March 6th. Canaccord Genuity Group boosted their price target on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research report on Wednesday, February 18th. Finally, Jefferies Financial Group cut Kenvue from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $23.00 to $18.00 in a research note on Friday, January 30th. Three investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to MarketBeat, Kenvue presently has an average rating of “Hold” and an average target price of $19.58.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.